Author Archives: Margarida Maia

Rezpeg tamps down disease activity; fails to meet ISLAND primary goal

A middle dose of rezpegaldesleukin, an experimental medicine being developed by Nektar Therapeutics, led to clinically meaningful gains in measures of disease activity in people with systemic lupus erythematosus (SLE). That’s according to top-line data from ISLAND (NCT04433585), a Phase 2 clinical study that evaluated how safe…

Urine Levels of G3BP Protein May Show Lupus Nephritis in SLE Patients

A test of galectin-3-binding protein (G3BP) levels in the urine is an easy way to distinguish lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), from other forms of lupus where the kidneys are not affected, a study suggested. Researchers also observed that protein levels…